• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Poll: What Were the Most Important Biosimilar Findings Presented at ASCO?

Article
Conference|ASCO

Diverse findings on biosimilar safety and savings were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting.

Which of these biosimilar presentations at ASCO was most important?

For patients receiving myelosuppressive chemotherapy for breast and lung cancer, same-day pegfilgrastim to combat febrile neutropenia is safe and effective.
In real-world studies, the trastuzumab biosimilars Kanjinti and Zedora demonstrate comparable safety vs Herceptin for breast and gastrointestinal cancer.
The Oncology Care Model lowers use of supportive-care medications and boosts filgrastim biosimilar use.
Oncologists’ use of 3 biosimilars soared from 2019 to 2020.
Texas Oncology’s automatic biosimilar switching program led to single-month savings of $4 million (21%) among 460 health care practitioners.
Recent Videos
Lakesha Farmer, PharmD
Adam Colborn, JD.
Prerakkumar Parikh, PharmD
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Julie Reed
Julie Reed, MS
Julie Reed, executive director of the Biosimilars Forum
Ryan Haumschild, PharmD, MS, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Related Content
Breast cancer research. | Image Credit: shidlovski - stock.adobe.com

Trastuzumab Biosimilar and Pertuzumab Effective, Safe in Neoadjuvant Breast Cancer Therapy

Cameron Santoro
September 19th 2024
Article

The combination of trastuzumab biosimilar and pertuzumab with chemotherapy was effective in treating HER2-positive breast cancer, offering high safety and affordability.

CFB podcast banner

Biosimilars Oncology Roundup for June 2024—Podcast Edition

Skylar Jeremias
July 7th 2024
Podcast

On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.

AI generated image depicting healthcare inflation | Image credit: Nitcharee - stock.adobe.com

Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline

Skylar Jeremias
August 3rd 2024
Article

Products in line to face biosimilar competition are projected to increase their list prices in advance, according to Vizient’s Pharmacy Market Outlook Report for Summer 2024.

CFB podcast banner

Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report

Skylar Jeremias
May 19th 2024
Podcast

The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.

Health care cost | Image credit: Kiattisak - stock.adobe.com

PBMs Drive Up Drug Costs, Squeeze Out Generics and Biosimilars, FTC Report Finds

Mary Caffrey
July 12th 2024
Article

A long-awaited report from the Federal Trade Commission (FTC) finds that vertical integration and consolidation have worked against consumers and independent pharmacies.

doctor with breast cancer ribbon | Image credit: Romolo Tavani - stock.adobe.com

Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer

Skylar Jeremias
July 9th 2024
Article

A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.

© 2024 MJH Life Sciences

All rights reserved.